[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
November 11, 2009

New Standards Reduce Heparin Potency

JAMA. 2009;302(18):1956. doi:10.1001/jama.2009.1615

Clinicians should be aware of new manufacturing controls that have decreased the potency of the anticlotting agent heparin by up to 10%, according to the US Food and Drug Administration (FDA).

The changes in manufacturing standards for heparin were developed by the US Pharmacopeia (USP), a nonprofit standards-setting organization, and are enforced by the FDA. While US manufacturers have labeled products that contain heparin based on USP standards, the recent changes modified the reference standard for the drug's unit dose to match the World Health Organization's International Standard unit dose that is used in Europe. The revision reduces the potency of heparin by about 10% when compared with the previous USP standard.

First Page Preview View Large
First page PDF preview
First page PDF preview
×